Zolbetuximab in Gastric or Gastroesophageal Junction Adenocarcinoma

The addition of zolbetuximab, an anti–claudin 18.2 antibody, to chemotherapy in gastric and gastroesophageal junction adenocarcinoma led to longer progression-free and overall survival than chemotherapy alone.

​   The New England Journal of Medicine: Search Results in Hematology/Oncology